By Lucy Parkinson, Director of Research, LSN
Diagnostics is a challenging landscape for fundraising and commercialization; however, the sector attracts interest and backing from a wide variety of stakeholders. There are many unmet needs in the sector, from finding new disease biomarkers to improving monitoring of progressive diseases.
The range of diagnostic investors attending RESI on MaRS next Tuesday provide testament to this varied landscape, with interest in novel diagnostic technologies coming from major pharma and device companies, diagnostic service providers, venture investors, and government organizations. RESI will bring the diagnostics world together for a panel discussion, moderated by Bob Williams, Vice President, Business Development and Innovation – Bracco Diagnostics, and featuring:
- Nicola Urbani, Investment Director, Emerillon Capital
- Lawrence Mahan, VP Sales and Marketing, LifeLabs
- Ihor Boszko, Vice President, Business Development, Ontario Genomics
- Lyon Wong, Co-Founder & General Partner, Spectrum 28
These investors will introduce their own specific angle on the diagnostics sector, and will cover what they look for in an investment opportunity in this sector. Panelists will also provide advice on how to make a new diagnostic catch their attention as an investable product. If you’d like to hear the advice of these experts at RESI, there’s still time to sign up.